{"status": "OK", "response": {"docs": [{"type_of_material": "Interactive Feature", "blog": [], "news_desk": "Health", "lead_paragraph": "Recently unsealed internal documents and depositions provide a window into the calculation made by Pfizer and its efforts to overcome doubts about its arthritis drug Celebrex.", "headline": {"main": "Combating Doubts About Celebrex"}, "abstract": null, "print_page": null, "word_count": "6", "_id": "53f82e6d7988105a425954c4", "snippet": "Recently unsealed internal documents and depositions provide a window into the calculation made by Pfizer and its efforts to overcome doubts about its arthritis drug Celebrex.", "source": "The New York Times", "slideshow_credits": null, "web_url": "http://www.nytimes.com/interactive/2012/06/25/health/25celebrex-document.html", "multimedia": [], "subsection_name": null, "keywords": [{"value": "Celebrex (Drug)", "is_major": "N", "rank": "1", "name": "subject"}, {"value": "Pfizer Inc", "is_major": "N", "rank": "2", "name": "organizations"}], "byline": null, "document_type": "multimedia", "pub_date": "2012-06-25T00:00:00Z", "section_name": "Health"}], "meta": {"hits": 1, "offset": 0, "time": 37}}, "copyright": "Copyright (c) 2013 The New York Times Company.  All Rights Reserved."}